← Back to Search

Taxane

Tesetaxel once every 3 weeks for Prostate Cancer

Phase 2
Waitlist Available
Led By Michael J Morris, MD
Research Sponsored by Genta Incorporated
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years following enrollment of the last subject
Awards & highlights

Study Summary

Given the activity of docetaxel in patients with progressive, metastatic castration-resistant prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years following enrollment of the last subject
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 years following enrollment of the last subject for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
Disease-control rate
Durable response among patients with measurable disease
Duration of response among patients with measurable disease
+5 more

Side effects data

From 2014 Phase 2 trial • 17 Patients • NCT01064713
23%
fatigue
15%
anorexia
15%
vomiting
15%
constipation
15%
muscle weakness
15%
taste alteration
15%
nausea
8%
peripheral neuropathies
8%
stomatitis
8%
chills
8%
headaches
8%
diarrhea
8%
pain
8%
heartburn
100%
80%
60%
40%
20%
0%
Study treatment Arm
40 Tesetaxel, Cohort A
50 mg Tesetaxel, Cohort B

Trial Design

1Treatment groups
Experimental Treatment
Group I: Tesetaxel once every 3 weeksExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tesetaxel
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Genta IncorporatedLead Sponsor
30 Previous Clinical Trials
1,613 Total Patients Enrolled
Michael J Morris, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
3 Previous Clinical Trials
452 Total Patients Enrolled
1 Trials studying Prostate Cancer
385 Patients Enrolled for Prostate Cancer

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
2011. "Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01296243.
All > Prostate
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top